Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

Delayed Quote. Delayed  - 07/22 10:03:20 pm
96.55 USD   -0.41%
07/23 CVS HEALTH : St. Johns Investment Management Company buys $1,105,897..
07/22 CVS HEALTH CORP : To Hold Second Quarter 2016 Conference Call
07/19 CVS HEALTH CORP : ex-dividend day
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Exclusive: Ernst, audit clients cut lobbying ties-records

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:11am CEST

Ernst & Young's lobbying unit is no longer listed as a lobbyist for three major U.S. companies, all of whom were 2011 audit clients of the accounting giant. The deregistration follows questions raised by two U.S. senators in March about whether the dual relationships crossed auditor independence boundaries.

Documents filed last month with Congress showed that Washington Council Ernst & Young, the E&Y unit, was no longer registered as doing lobbying work for Amgen Inc (>> Amgen, Inc.), CVS Caremark Corp (>> CVS Caremark Corporation) and Verizon Communications Inc (>> Verizon Communications Inc.).

A lobbying-contract termination was also filed on March 31 for a fourth company, Nomura Holdings Inc (>> Nomura Holdings Inc.), which, according to securities filings, uses an E&Y affiliate for auditing services. E&Y had provided lobbying services to Nomura since June 2011, according papers on file with Congress.

Auditors that review corporations' books every year must follow rules limiting other ties with audit clients. The rules - meant to prevent auditors from getting too cozy with audit clients - were substantially beefed up a decade ago after a rash of accounting scandals at Enron Corp. and other companies.

An Ernst & Young spokesman declined to comment on the discontinued lobbying relationships. Officials with Nomura, Verizon and CVS declined to comment. Amgen officials could not immediately be reached for comment.

The chief accountant for the U.S. Securities and Exchange Commission, James Kroeker, speaking at a financial reporting conference at Baruch College in New York on Thursday, said SEC rules state an auditor should not act in an advocacy role for a company it audits and lobbying would be inconsistent with that.

Kroeker did not mention any audit firms by name.

He said: "If you think about lobbying in the traditional sense, you would say, 'wouldn't somebody that's lobbying be placing themselves in a position to be an advocate?'"

Asked whether the SEC was looking into E&Y's lobbying activities, an official in the agency's enforcement division declined to comment because its investigations are not public.

"We are aware of it and we are cognizant of what the rules are," said Howard Scheck, chief accountant of the SEC's division of enforcement, on the sidelines of Thursday's conference.

"If there's a violation that we find, we'll certainly do something about that," he said, without referring to E&Y.

Reuters reported in March that Washington Council Ernst & Young had been hired as a lobbyist for a number of E&Y's audit clients, prompting two lawmakers to demand closer scrutiny.

Democratic senators Carl Levin and Jack Reed both expressed concerns at the time and urged the SEC to look into the matter. On Thursday, Reed's office did not immediately respond to inquiries seeking comment. Levin's office declined to comment.

Verizon had a particularly long relationship with E&Y's lobbyists, who helped the telecommunications company with tax issues beginning in September 2001. The two other lobbying relationships were more recent, dating to February in the case of Amgen and September in the case of CVS Caremark. Both contracts were connected to corporate tax debates. The three U.S. terminations were all effective March 31 and Nomura's termination was filed the same day.

The E&Y spokesman referred Reuters to its earlier statement that Washington Council's work complied with independence rules.

The work was approved by clients' audit committees and it was limited to tax-related issues, E&Y spokesman Charles Perkins said when Reuters reported on the issue in March.

Washington Council did not solicit votes on legislation for E&Y audit clients, Perkins said.

The Public Company Accounting Oversight Board, the watchdog for U.S. auditors, is looking to shore up independence rules after finding numerous instances in which auditors did not dig deeply enough to challenge clients' financial numbers.

The SEC's Kroeker said he was encouraged to see the board tackling the subject.

"Independence is really the bedrock, the foundation of the value that's provided by a third-party audit," he said.

(Reporting by Dena Aubin and David Ingram; Additional reporting by Kim Dixon; Editing by Kevin Drawbaugh and Matt Driskill)

By David Ingram and Dena Aubin

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
07/23 CVS HEALTH : St. Johns Investment Management Company buys $1,105,897 stake in CV..
07/22 CVS HEALTH CORPORATION : To Hold Second Quarter 2016 Conference Call
07/21 CVS HEALTH : Lipinski Announces Installation of Drop Box for Unwanted Prescripti..
07/19 CVS HEALTH CORP : ex-dividend day
07/18 CVS HEALTH : Free Clinic receives $10,000 grant from CVS
07/15 CVS HEALTH : Specialty Pharmacy Facility Opens in Orlando
07/15 CVS HEALTH : Research Institute Study Shows that Medication Reconciliation Progr..
07/14 CVS HEALTH : Foundation and American Academy of Pediatrics Announce New Initiati..
07/14 CVS HEALTH : FENWAY PARK Burlington veteran attends baseball camp
07/14 CVS HEALTH : Honor Local veterans honored at Fenway Park
More news
Sector news : Drug Retailers - NEC
07/21 MCKESSON : Theranos hires executives in regulatory, compliance push
07/21DJTheranos Hires Compliance, Regulatory Executives
07/21DJSINOPHARM : to Inject Certain Assets Into China National Medicines for CNY5.37 B..
07/18DJStarbucks Widens Workers' Health-Insurance Options
07/13DJWALGREENS BOOTS ALLIANCE : Boosts Its Quarterly Dividend 4.2%
More sector news : Drug Retailers - NEC
News from SeekingAlpha
07/22 6 MONTH PORTFOLIO UPDATE : Good News, Double-Digit Increase In Both Income And V..
07/22 CVS HEALTH : Stock Valuations Are Compelling
07/21 CONSUMER STAPLES : Finding Value In An Expensive Sector
07/21 The Happy Gilmore Market And My Search For Attractive Multiples At Today's Pr..
07/21 Risk-Reward Of The Market - Cramer's Mad Money (7/20/16)
Advertisement
Financials ($)
Sales 2016 181 303 M
EBIT 2016 10 754 M
Net income 2016 5 791 M
Debt 2016 25 246 M
Yield 2016 1,69%
P/E ratio 2016 17,77
P/E ratio 2017 15,50
EV / Sales 2016 0,71x
EV / Sales 2017 0,65x
Capitalization 103 697 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 112 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-1.25%103 697
WALGREENS BOOTS ALLIAN..-4.47%88 047
EXPRESS SCRIPTS HOLDIN..-9.78%49 903
MCKESSON CORPORATION-0.33%44 365
CARDINAL HEALTH INC-7.03%27 039
AMERISOURCEBERGEN CORP..-17.21%18 533
More Results